<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intravenous immune globulin: Adverse effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intravenous immune globulin: Adverse effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intravenous immune globulin: Adverse effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elena E Perez, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nadine Shehata, MD, MSc, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jordan S Orange, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is a product prepared from human plasma used to treat a variety of immunodeficiency, inflammatory, and autoimmune conditions.
        </p>
        <p>
         This topic review discusses potential adverse reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , along with strategies to minimize these reactions and our approach to treatment.
        </p>
        <p>
         Separate topic reviews discuss the clinical uses of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and products for subcutaneous (SC) and intramuscular (IM) administration:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products – (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SC and IM products – (See
         <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">
          "Subcutaneous and intramuscular immune globulin therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of immunoglobulin products to treat immunodeficiencies – (See
         <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">
          "Immune globulin therapy in inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H656341">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H656383">
         <span class="h2">
          Terminology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (also called immunoglobulin, immune serum globulin [ISG], or gamma globulin) is an antibody-containing product purified from large pools (&gt;10,000 liters) of human plasma using techniques that separate the immunoglobulin fraction from other proteins and plasma constituents. (See
         <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">
          "Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'Purification methods'
         </a>
         .)
        </p>
        <p>
         Hyperimmune globulins refer to products made from plasma with a high titer of the desired antibody. Some hyperimmune products are derived from immunized animals (eg, equine products) such as
         <a class="drug drug_general" data-topicid="8900" href="/z/d/drug information/8900.html" rel="external">
          diphtheria antitoxin
         </a>
         or snake anti-venoms. These products are much more likely to have adverse reactions, which are outside the scope of this topic review.
        </p>
        <p>
         Products for intravenous use are referred to as intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) by clinicians and as "IGIV" by industry and regulatory agencies.
        </p>
        <p>
         Other human
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         preparations include subcutaneous immune globulin (SCIG; IGSC, SC ISG), hyaluronidase-facilitated SCIG (fSCIG), and intramuscular immune globulin (IMIG; IGIM, IM ISG). IMIG is rarely used because it has few if any advantages over subcutaneous or intravenous products.
        </p>
        <p class="headingAnchor" id="H656348">
         <span class="h2">
          Incidence and risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse reactions are reported to occur in 5 to 15 percent of all
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions and affect 20 to 50 percent of individuals receiving IVIG [
         <a href="#rid1">
          1-7
         </a>
         ].
        </p>
        <p>
         More than half of reactions occur in the immediate period during or within a few hours of the infusion, especially with the first infusion or after changing products [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Anaphylaxis and anaphylaxis-like reactions'
         </a>
         below and
         <a class="local">
          'Other immediate reactions'
         </a>
         below.)
        </p>
        <p>
         In children, the incidence of adverse effects was evaluated in a prospective series of 345
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions administered to 58 children (33 for immunodeficiency and 25 for immunomodulation; median age, four years) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse events occurred in 40 percent of patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immediate adverse reactions were seen in 3.5 percent of the infusions and delayed reactions in 20.9 percent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache was the most common reaction (24 percent of patients, 13 percent of infusions) and most often occurred as a delayed reaction.
        </p>
        <p>
        </p>
        <p>
         Other common reactions include fatigue, abdominal pain, and myalgia [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         The risk of adverse reactions generally correlates with the dose of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         within each course and the rate of infusion. Many of the known adverse reactions are more likely to occur during the first infusion, or the first infusion of a new product after changing brands. This was illustrated in a review of 15,548 infusions administered to 1705 patients, in which only 10 individuals had an adverse systemic reaction to a product they had previously received [
         <a href="#rid12">
          12
         </a>
         ]. Adverse reactions are uncommon in patients receiving IVIG on a regular schedule [
         <a href="#rid1">
          1,2,13
         </a>
         ].
        </p>
        <p>
         Most adverse reactions are mild, transient, reversible events such as headache, chills, or flushing. Potentially serious reactions occur in 2 to 6 percent of patients [
         <a href="#rid14">
          14
         </a>
         ]. Product information includes a Boxed Warning regarding the risks of thrombosis, kidney dysfunction, and acute kidney injury [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The underlying clinical condition may also affect the risk spectrum of adverse events. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of 13,508
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions in 459 patients with primary antibody deficiencies, the presence of a concomitant infection increased the risk compared (5.1 percent, versus 0.5 percent in individuals without an infection) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 54 patients with neuromuscular disorders treated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , the risk of severe headaches and aseptic meningitis was greater in individuals with a history of migraine than in those without a migraine history (4 of 8 [50 percent] versus 2 of 46 [4 percent]) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional general risk factors include hyperviscosity states (either from dehydration or a hyperviscosity syndrome due to cryoglobulins or paraproteins), underlying organ dysfunction (eg, kidney disease), and/or prothrombotic stimuli (eg, systemic inflammatory state or central venous catheter). Other risk factors in adults include coronary artery disease, hypertension, smoking, hyperlipidemia, diabetes mellitus, age &gt;65 years, sepsis, immobility, and concomitant use of estrogens or nephrotoxic agents [
         <a href="#rid2">
          2,4,16,17
         </a>
         ]. Adverse events also can occur in individuals who lack predisposing factors.
        </p>
        <p>
         Changing from a well-tolerated product to another product should be avoided when possible, and changes should not be made without the consent of the patient's clinician [
         <a href="#rid14">
          14
         </a>
         ]. Patients initiating
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         therapy, or those switching between products, should be observed closely by a clinician who is familiar with the signs and symptoms of IVIG reactions [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Change of products'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H656376">
         <span class="h2">
          Classification of reaction types
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         can be classified in several ways (by severity, affected organ system, timing of onset, or mechanism).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity
         </strong>
         – The majority of adverse reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         are mild and transient. Potentially severe reactions include anaphylaxis in some immunoglobulin A (IgA)-deficient individuals and thromboembolic events including myocardial and cerebral ischemia, impaired kidney function, aseptic meningitis, or severe hemolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organ system
         </strong>
         – Organ systems that may be affected include the kidney, lungs, skin, central nervous system, gastrointestinal system, and hematopoietic system, including red blood cells (RBCs), particularly hemolytic reactions. Systemic reactions such as anaphylaxis and vascular/thromboembolic complications can affect multiple organ systems.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing
         </strong>
         – Immediate reactions occur during or within six hours following the infusion and include IgE-mediated anaphylaxis and rate-related reactions such as headache, fever/chills (especially in patients with active infections), and infrequently thromboembolic events. Delayed reactions occur hours to days following the infusion and include headache/aseptic meningitis, acute kidney injury, hemolysis, and thromboembolic events such as venous thrombosis, myocardial infarction, transient ischemic attack, and stroke.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism
         </strong>
         – Potential mechanisms of adverse reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include immune reactions such as complement activation. These may be caused by components in the product (coagulation factors or vasoactive enzymes such as kallikreins) or a reaction to them. Other mechanisms are related to an antibody specificity (hemolytic anemia from isoagglutinins [antibodies to RBC antigens such as A, B, or RhD], although newer products undergo added steps to reduce hemolysis), reactions related to active non-IgG proteins in the product (one product since removed from the market contained an activated clotting factor (see
         <a class="local">
          'Thromboembolic events'
         </a>
         below)), and reactions related to excipients such as sucrose (subsequently removed from all products) or the osmotic and/or free water load of the infusion [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         An approach to distinguishing among some of the immediate reactions is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef96323" href="/z/d/graphic/96323.html" rel="external">
          algorithm 1
         </a>
         ), with the caveat that many
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions occur in the home or an outpatient setting without access to full radiology and laboratory services.
        </p>
        <p class="headingAnchor" id="H2096741363">
         <span class="h2">
          Comparison with subcutaneous products
         </span>
         <span class="headingEndMark">
          —
         </span>
         SCIG has a lower rate of adverse effects than IVIG and is appropriate for some conditions such as patients with immunodeficiency, as these patients generally require lower doses of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         . One SCIG preparation is approved for use at the larger doses needed for chronic inflammatory demyelinating polyneuropathy (CIDP) and provides another treatment option for these patients [
         <a href="#rid18">
          18
         </a>
         ]. Adverse effects of SCIG are mostly local reactions at the injection site(s). Some side effects from SCIG can be mitigated by more frequent infusion of smaller volumes (eg, dosing multiple times per week instead of weekly or every two weeks).
        </p>
        <p>
         Other differences between SCIG and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         are described separately. (See
         <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">
          "Subcutaneous and intramuscular immune globulin therapy", section on 'Comparison of SCIG with IVIG'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H658008">
         <span class="h1">
          STRATEGIES FOR REDUCING ADVERSE EVENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of strategies are used clinically for minimizing the risk of adverse reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ]. These are summarized in the table  (
         <a class="graphic graphic_table graphicRef129468" href="/z/d/graphic/129468.html" rel="external">
          table 1
         </a>
         ) and discussed below. It is helpful to reassure patients that minor adverse effects are common and generally improve over time.
        </p>
        <p class="headingAnchor" id="H2037462212">
         <span class="h2">
          Precautions in all patients
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapeutic immunoglobulins should only be given for appropriate indications, as discussed in individual disease-specific topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Clinical uses'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration by the subcutaneous route may reduce the risk of some reactions. Conditions in which this may be appropriate (typically immunodeficiencies) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">
          "Subcutaneous and intramuscular immune globulin therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should be adequately hydrated prior to starting the infusions. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Prehydration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slow infusion rates, with gradual stepwise increases, are suggested for new patients or when products are changed. Stepwise increases in rates following an initially slow infusion are also appropriate for individuals receiving regular
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Infusion rates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once a product has been established to be safe and effective for a given patient, substitutions of other products should be avoided. Changes should be made only if there is a clear clinical rationale and the prescribing clinician and patient agree. (See
         <a class="local">
          'Change of products'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients or designated providers should keep a record of all lots of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and any other blood products received, in case a "look back" is ordered. Most vials of IVIG have a perforated sticker that can be removed and kept in the patient's personal log book, or the lot number can be requested from the hospital pharmacy or other provider. Practices differ; in many cases the transfusion medicine service or infusion center is responsible for documenting lot numbers. For patients receiving IVIG at home, the specialty pharmacy usually tracks the lot numbers dispensed. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Consent and record keeping'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H948893556">
         <span class="h2">
          Precautions in specific populations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with a suspected bacterial infection should receive antibiotic therapy before the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion to reduce the risk of an excessive inflammatory reaction. (See
         <a class="local">
          'Pain or systemic (influenza-like) symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who develop anaphylaxis and who have very low or undetectable IgA levels (&lt;5 to 7 mg/dL) and IgE anti-IgA antibodies require special attention and should switch to subcutaneous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (SCIG) or receive a product with low IgA; premedications may also be appropriate. This situation is very rare; many individuals with low or absent IgA are able to tolerate IVIG regardless of the IgA content. (See
         <a class="local">
          'Anaphylaxis and anaphylaxis-like reactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are prone to headaches or have a history of migraine are at increased risk for headaches with infusion and can take a nonsteroidal antiinflammatory drug (NSAID) or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         prior to, or at the time of,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion. Specific regimens and additional measures for more refractory headaches or delayed-onset aseptic meningitis are discussed below. In addition, it can be helpful to remind patients to ensure they are well hydrated the day before and for a day or two after infusion. (See
         <a class="local">
          'Headache and migraine (acute or delayed)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients at increased risk of thromboembolic complications, or those who have had prior thromboembolic complications, may benefit from additional preventive measures including preinfusion hydration and avoidance of prolonged immobility (eg, airplane travel) in the few days following the infusion, although there is no high-quality evidence to support most of these interventions specifically in individuals receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . (See
         <a class="local">
          'Thromboembolic events'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients at increased risk of acute kidney injury or those with underlying chronic kidney disease may be given intravenous fluids before beginning the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion to avoid hyperviscosity. (See
         <a class="local">
          'Complications affecting the kidney'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional measures may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the patient cannot tolerate a more concentrated solution, 5 percent IgG solutions are available  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         doses (1 to 2 grams/kg) should be divided into smaller doses given on different days, particularly in older adults.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2962524629">
         <span class="h2">
          Premedications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Premedications are not needed in all patients. Premedications may be useful for preventing reactions in individuals who have experienced specific reactions with previous administration. (See
         <a class="local">
          'Anaphylaxis and anaphylaxis-like reactions'
         </a>
         below and
         <a class="local">
          'Headache and migraine (acute or delayed)'
         </a>
         below.)
        </p>
        <p>
         Our approach to deciding whether to use premedications is illustrated in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130102" href="/z/d/graphic/130102.html" rel="external">
          algorithm 2
         </a>
         ) and includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who have had a prior mild reaction with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         such as urticaria/hives, headache, chills, nausea, or myalgias, we suggest premedication. However, not administering premedication is also reasonable if the individual prefers. The specific combination of medications and their dosing is individualized; medications often include
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         or a nonsteroidal antiinflammatory drug (NSAID), with or without
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         . Glucocorticoids are sometimes used, but we suggest avoiding these if possible, especially in individuals who are already immunosuppressed. These mild early reactions often subside with time, and the need for premedications should be revisited in individuals receiving regular infusions. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Premedications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who have tolerated previous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions without a prior reaction are likely to tolerate subsequent infusions and generally do not require premedications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Practices vary for the first dose of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (unknown whether a reaction will occur).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some clinicians prefer to avoid premedications with the first dose of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , as this reduces the costs and time required to administer IVIG and avoids potential adverse effects from premedications that may not be necessary. Appropriate medications can be made available and can be taken if a mild reaction occurs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other clinicians prefer to administer premedications to all individuals receiving a first dose of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , as this may improve tolerability and avoid reactions in some cases. If the IVIG infusion is tolerated, the premedications can be omitted with subsequent infusions.
        </p>
        <p>
        </p>
        <p>
         Further discussion of premedications is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Premedications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3188308186">
         <span class="h2">
          Change of products
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many strategies may be used to prevent or reduce infusion reactions, including reducing the rate of the infusion, switching to a different route (from intravenous to subcutaneous) if feasible, or providing premedications, as described above (see
         <a class="local">
          'Premedications'
         </a>
         above).
        </p>
        <p>
         Changing products when a patient is tolerating infusions is generally avoided but may be tried when an individual is experiencing side effects if all other measures are unsuccessful. (See
         <a class="local">
          'Strategies for reducing adverse events'
         </a>
         above.)
        </p>
        <p>
         Adverse effects may be more frequent and/or more severe whenever a new product is used. For this reason, extra caution and slow infusion rates should be used when changing the specific product used by any individual patient. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Infusion rates'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H551276586">
         <span class="h1">
          ANAPHYLAXIS AND ANAPHYLAXIS-LIKE REACTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2063752135">
         <span class="h2">
          Overview of anaphylaxis and other immune reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         may develop true anaphylaxis or reactions resembling anaphylaxis [
         <a href="#rid20">
          20
         </a>
         ]. Anaphylaxis during IVIG administration is extremely rare, but it may be life-threatening [
         <a href="#rid21">
          21
         </a>
         ]. The diagnosis is made clinically based on signs and symptoms  (
         <a class="graphic graphic_figure graphicRef82831" href="/z/d/graphic/82831.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Anaphylaxis is a systemic reaction characterized by any combination of generalized hives, pruritus or flushing, angioedema (often of the face or lips), respiratory compromise, nausea or vomiting, or hypotension. (See
         <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">
          "Anaphylaxis: Acute diagnosis", section on 'NIAID/FAAN diagnostic criteria'
         </a>
         .)
        </p>
        <p>
         Laboratory testing such as a serum tryptase level cannot be used to confirm or exclude the diagnosis of anaphylaxis rapidly enough to impact management; however, laboratory results from samples obtained at the time of the event can help to determine retrospectively if the reaction was anaphylaxis and may be useful for guiding future therapies. (See
         <a class="medical medical_review" href="/z/d/html/389.html" rel="external">
          "Laboratory tests to support the clinical diagnosis of anaphylaxis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          True or suspected anaphylaxis
         </strong>
         – True or suspected anaphylaxis with hypotension and/or respiratory compromise is a medical emergency and should be treated rapidly with immediate discontinuation of the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion and administration of intramuscular
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         and other therapies, which are delineated in rapid overview tables for children  (
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ) and adults  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         True anaphylaxis is a rare (prevalence, 1 in 20,000 to 1 in 50,000), histamine-mediated reaction that can cause potentially life-threatening cardiovascular and/or respiratory compromise. The prevalence has likely decreased further with improved manufacturing processes. When it occurs, there appears to be an association between anaphylaxis mediated by anti-IgA antibodies in individuals with very low or absent IgA levels; however, larger studies are needed to evaluate such an association and to determine specific risk factors. Very low or absent IgA may be seen in individuals with IgA deficiency or common variable immune deficiency (CVID), and anti-IgA antibodies are typically of the IgE or IgG class (predominantly IgE) [
         <a href="#rid22">
          22,23
         </a>
         ]. However, the role of anti-IgA antibodies in causing anaphylaxis in IgA-deficient patients receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         therapy remains controversial [
         <a href="#rid21">
          21
         </a>
         ]. IgG anti-IgA is common in IgA-deficient patients and often does not lead to anaphylaxis. Routine use of low IgA products is not necessary in all individuals with low IgA levels in the absence of an adverse event. Additional information about testing for anti-IgA is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3936.html" rel="external">
          "Selective IgA deficiency: Management and prognosis", section on 'Reactions to blood products'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with hypogammaglobulinemia due to nephrotic syndrome or protein-losing gastroenteropathy are far less likely to develop anti-IgA antibodies [
         <a href="#rid20">
          20
         </a>
         ]. Anaphylactic reactions can occur in which IgE from the donor reacts with an antigen in the recipient, but these reactions are rare. (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions", section on 'Anaphylactic transfusion reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other allergic and immune reactions
         </strong>
         – Urticaria, flushing, pain in the chest or lower back, nausea and/or vomiting, and/or a sense of impending doom or sudden anxiety are usually rate related and often occur midway through an
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion. Tachycardia and/or tachypnea may also be present. Various combinations of symptoms may occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to check pulse, blood pressure, respiratory rate, and oxygen saturation prior to and during the infusion for any clinically significant changes. The infusion rate at the time the symptoms began to appear should be noted. If symptoms or other findings suggest a severe reaction, the infusion is stopped and the patient is treated accordingly. If symptoms are mild, the infusion may be held temporarily and restarted at a lower rate if symptoms resolve (eg, reduce the rate by 50 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reactions resembling anaphylaxis, such as those that include chest tightness, wheezing, and/or dyspnea, are more common than true anaphylaxis, and may be difficult to distinguish from true anaphylaxis at the outset. The subsequent course of the reaction and laboratory testing (eg, for IgE anti-IgA or tryptase) may allow categorization of these reactions. Unlike IgE-mediated anaphylaxis, these reactions are often accompanied by increases in blood pressure, rather than reductions. However, hypotension unrelated to an IgE-anti-IgA reaction may occur. Also, unlike true anaphylaxis, which may become more severe upon re-exposure to the antigen, these reactions tend to become milder with subsequent infusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mechanism of anaphylaxis-like reactions is unknown. Possible contributing factors include complement activation by aggregates of IgG or immune complexes, reactions to active kinins or kallikrein in the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         product, secretion of prostaglandins or other eicosanoids in response to the IVIG, and/or release of cytokines in response to cross-linking of Fc-gamma receptors on lymphocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TRALI
         </strong>
         – Transfusion-related acute lung injury (TRALI) is a type of transfusion reaction characterized by the sudden onset of hypoxemic respiratory insufficiency during or shortly after transfusion of a blood product. The mechanism in patients receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is likely to involve activation of neutrophils by anti-leukocyte/anti-HLA antibodies in the IVIG and/or rapid complement activation [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TRALI can cause respiratory distress similar to anaphylaxis, but TRALI is less likely to be associated with airway signs and symptoms such as stridor, cough, wheezing, and nasal congestion. TRALI does not cause urticaria, and gastrointestinal symptoms such as nausea and/or vomiting are uncommon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific diagnostic criteria and management of TRALI are summarized in the tables  (
         <a class="graphic graphic_table graphicRef64212" href="/z/d/graphic/64212.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef122227" href="/z/d/graphic/122227.html" rel="external">
          table 6
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)", section on 'Blood component risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H707760909">
         <span class="h2">
          Management and future prevention
         </span>
        </p>
        <p class="headingAnchor" id="H3574923679">
         <span class="h3">
          Preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications and resuscitation equipment should be immediately available to treat anaphylaxis in all individuals, especially those known to be IgA-deficient. Many clinicians prefer to administer the initial dose in a monitored setting. In some countries, including the United States, patients are often prescribed
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         autoinjectors when
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is administered at home.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergency treatment
         </strong>
         – If anaphylaxis with hypotension occurs, rapid treatment should be initiated with intramuscular
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         and other therapies as described in the rapid overview tables for children  (
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ) and adults  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testing for anti-IgA
         </strong>
         – We do not routinely measure anti-IgA antibodies in patients with IgA deficiency prior to giving an
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion, because the majority of patients with IgA deficiency tolerate IVIG products, including those with anti-IgA [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, testing is reasonable in those who have had an anaphylactic or a possible anaphylactic reaction and are expected to require additional infusions of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or blood transfusions in the future. The particle gel immunoassay method is reliable and rapid [
         <a href="#rid25">
          25
         </a>
         ]. Anti-IgA testing (especially for IgG anti-IgA) is available from several academic and commercial laboratories.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If testing is not available, switching to subcutaneous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (SCIG) or a low IgA product is reasonable, in addition to using premedications, depending on the severity of the reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventive strategies for future infusions
         </strong>
         – Various approaches can be considered to reduce the risk of anaphylaxis in the future. Strategies to reduce the risk of future reactions include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Switching to a SCIG product for individuals receiving lower doses of IgG (eg, for primary or secondary immunodeficiency). SCIG is often tolerated, even in individuals with anti-IgA antibody [
         <a href="#rid26">
          26
         </a>
         ]. The reason for reduced reactions to SCIG products is unclear, as these products contain IgA; it may involve induction of tolerance, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">
          "Subcutaneous and intramuscular immune globulin therapy", section on 'IgA-deficient patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Switching to an
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         product with low IgA content [
         <a href="#rid26">
          26
         </a>
         ]. The available products vary widely in IgA content, ranging from less than 1 mcg/mL to greater than 600 mcg/mL  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ). The individual should receive pretreatment or concomitant treatment with antihistamines and/or glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Premedications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some clinicians administer premedications to individuals with IgA deficiency who have not had a previous reaction, and if the initial infusion is tolerated, the premedications can be reduced gradually with subsequent infusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For individuals with a previous anaphylactic reaction who receive another
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         product, it is prudent to use an initially slow rate of administration (eg, 0.001 mL/kg/minute), giving a test dose first with 1 mL and then with 10 mL. If the patient tolerates the initial infusion, the rate of administration for the remainder of the product can be increased. If a winged infusion set (butterfly needle) is being used, it is also prudent to secure IV access with a separate line, in case fluids or additional medications are needed to manage a recurrent reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence
         </strong>
         – The evidence linking anti-IgA antibodies with anaphylaxis to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is weak, and pathophysiology of these reactions remains controversial [
         <a href="#rid20">
          20,21,27
         </a>
         ]. In principle, the immune system of an individual with serum IgA levels that are undetectable or &lt;5 to 7 mg/dL could recognize IgA in the IVIG product as a novel or foreign antigen and produce anti-IgA. Among patients with very low or undetectable serum IgA, anaphylaxis is more likely in disorders in which other antibody production is still possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In contrast, anaphylaxis is less likely in individuals with partial IgA deficiency (low but detectable levels of circulating IgA), since IgA would not appear as a novel antigen, although these patients may have other serious reactions to blood or plasma products. Anaphylaxis is not usually a concern in patients with X-linked (Bruton's) agammaglobulinemia, because those patients cannot make antibodies at all or only to a very limited degree. (See
         <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">
          "Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When present, anti-IgA antibodies may be of the IgG or IgE class; IgG is more commonly identified and may activate basophils [
         <a href="#rid23">
          23,28-30
         </a>
         ]. A 2017 review evaluated 23 reports of anaphylaxis associated with anti-IgA antibodies of the IgG class, and three reports of anaphylaxis associated with IgE antibodies to IgA [
         <a href="#rid20">
          20
         </a>
         ]. These were the only reported cases from the 1960s to the time of publication. The prevalence of these antibodies was particularly high in patients with the combination of IgA and IgG2 subclass deficiency (ie, 29 percent), yet most patients with anti-IgA antibodies tolerate
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         without incident, even products that are not specifically designated as low in IgA. A 2012 review of the literature identified 49 patients with IgA deficiency and IgG anti-IgA who tolerated IVIG [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2380969604">
         <span class="h3">
          Patients who do not have true anaphylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         It may be determined in retrospect that an individual had a reaction that was not true anaphylaxis, supported by one or more of the following findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension rather than hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urticaria that did not progress to true anaphylaxis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meeting criteria for TRALI  (
         <a class="graphic graphic_table graphicRef122227" href="/z/d/graphic/122227.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum IgA testing revealing presence of IgA
        </p>
        <p>
        </p>
        <p>
         Normal serum tryptase is consistent with a non-anaphylactic reaction but cannot be used to exclude anaphylaxis; some individuals with true anaphylaxis have a normal tryptase level. The sensitivity and specificity of this testing are not well-established, and the test needs to be done as soon as possible after the reaction (within 15 minutes and up to three hours), as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/389.html" rel="external">
          "Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Tryptase'
         </a>
         .)
        </p>
        <p>
         Clinicians may delay testing of IgA levels following
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion so as not to mistake IgA from the product as the patient's IgA (a theoretical concern). For most individuals with immunodeficiency, the information will already be available.
        </p>
        <p>
         In individuals who are established to have an allergic, nonanaphylactic reaction, symptoms such as urticaria often diminish with subsequent infusions. It may be possible to temporarily stop the infusion, treat with an antihistamine and/or glucocorticoids and continue the infusion if symptoms resolve, as long as prior similar reactions have been determined not to be true anaphylaxis based on the findings listed above. (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions", section on 'Allergic reactions'
         </a>
         .)
        </p>
        <p>
         Other clinicians or patients may prefer to use strategies identified for true anaphylaxis, such as switching to an SCIG product, out of an abundance of caution. (See
         <a class="local">
          'Preparation'
         </a>
         above.)
        </p>
        <p>
         In individuals who are determined to have TRALI rather than anaphylaxis, the implicated
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         product is not used for future infusions; the reaction is not expected to recur with subsequent IVIG. (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          OTHER IMMEDIATE REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immediate reactions are those that happen during or within six hours of the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion; these represent 60 percent of adverse IVIG reactions [
         <a href="#rid2">
          2
         </a>
         ]. Systemic reactions during the infusion are especially common in patients receiving their first infusion of IVIG, changing to a different IVIG product, or resuming treatment after missing several doses.
        </p>
        <p>
         Potential immediate reactions include rate-related reactions in individuals with or without a concurrent infection or a non-IgE-mediated allergic reaction due to an immune mediator in the product or elicited by the product. These reactions are rarely serious, but they can be distressing to the patient.
        </p>
        <p>
         Local reactions at the administration site (eg, pain, bleeding, bruising) are less common with IVIG, compared with either subcutaneous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (SCIG) or intramuscular immune globulin (IMIG) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Simply stopping the infusion until symptoms subside spontaneously and/or have been treated may be sufficient management in many cases. In most instances, the infusion may then be restarted at a lower rate. Severe reactions require subsequent supervised infusions.
        </p>
        <p>
         The different types of immediate reactions, as well as preventive measures and treatments, are discussed in this section and summarized in the table  (
         <a class="graphic graphic_table graphicRef129468" href="/z/d/graphic/129468.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H659714">
         <span class="h2">
          Pain or systemic (influenza-like) symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pain or systemic symptoms can be due to phlogistic reactions; these include generalized inflammatory symptoms that may accompany the use of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , especially in patients with an acute infection. This may be more likely in patients with an underlying immunodeficiency that puts them at risk of bacterial infections. Often, the reaction occurs in the setting of a chronic sinus or pulmonary infection. Symptoms may be especially pronounced if the infection has not been treated with antibiotics and the patient is receiving IVIG for the first time.
        </p>
        <p>
         Symptoms may resemble those that accompany the onset of infection in individuals with intact immune function. Examples include chills (and even rigors), fever, flushing, myalgias (eg, back pain), arthralgias, malaise, nausea, vomiting, and/or headache [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         These symptoms are thought to result from interactions of the newly delivered antibodies with bacterial antigens, neoantigens in the patient, or pathologic autoantibodies in the patient. Bacterial lipopolysaccharide (LPS) or other products released from newly opsonized organisms may also stimulate toll-like receptors and activate leukocytes and macrophages leading to rapid release of cytokines and/or eicosanoids.
        </p>
        <p>
         When possible, patients with immunodeficiency should have a thorough search for any occult infections and should receive appropriate antibiotics if an infection is identified, before receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . In such cases, a one to two day delay in administering IVIG is appropriate, provided the infection is resolving (absence of severe fever or other acute symptoms). However, the initiation of IVIG should not be delayed for longer than one to two days in patients who have an infection that has not responded to routine antimicrobial therapy. (See
         <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">
          "Immune globulin therapy in inborn errors of immunity", section on 'Initial doses and schedules'
         </a>
         .)
        </p>
        <p>
         The inflammatory symptoms may be minimized by giving the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         slowly and/or premedicating with antipyretics and/or glucocorticoids, as described above. (See
         <a class="local">
          'Strategies for reducing adverse events'
         </a>
         above.)
        </p>
        <p>
         If symptoms occur despite a delay in
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         administration, management generally involves temporarily interrupting the infusion and/or treating specific symptoms.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flushing, gastrointestinal symptoms, headache, back pain, and chest pain may be treated with a nonsteroidal antiinflammatory drug (NSAID) or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         .
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         should be avoided in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More severe back or chest pain may require opioid analgesics, but opioids are rarely needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          Diazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         may be used for rigors, muscle spasm, or severe musculoskeletal pain.
        </p>
        <p>
        </p>
        <p>
         However, clinicians should be aware that high-quality evidence to support this practice is lacking.
        </p>
        <p>
         Treatment of nausea and vomiting is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126279927">
         <span class="h2">
          Headache and migraine (acute or delayed)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Headache is a common side effect of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in children and adults. This was illustrated in a prospective study that evaluated adverse effects resulting from 345 IVIG infusions in 58 children [
         <a href="#rid9">
          9
         </a>
         ]. Headache was the most common adverse event, often lasting more than a day and sometimes resulting in absence from school.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Headache at the time of the infusion
         </strong>
         – Additional preventive measures may include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         at a slower rate
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adequate hydration
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Premedication
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For any type of headache,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         or a second-generation antihistamine can be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those with a history of migraine-like symptoms,
         <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">
          cyproheptadine
         </a>
         may be used. Cyproheptadine is an antihistamine and serotonin receptor antagonist that can be given at a dose of 2 to 4 mg for children or 4 to 12 mg for adults and repeated at the first sign of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Patients with a history of migraine can also premedicate with other types of antimigraine preparations [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">
          "Preventive treatment of migraine in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">
          "Preventive treatment of episodic migraine in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If anti-migraine therapies are ineffective in preventing symptoms, premedication with a glucocorticoid may be used. Examples include
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         at a dose of 0.5 to 1 mg/kg or equivalent in divided doses in children, or 30 to 60 mg in adults. Intravenous
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         may also be used, at a dose of 2 mg/kg in children or 50 mg in adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For post-infusion headaches accompanied by fever and/or signs of meningismus, premedication with a glucocorticoid may be tried, since these findings may be triggered by immunologic reactions within the central nervous system. In some cases, one or more of these medications may be required for as long as 72 hours after the infusion is completed. However, glucocorticoids do not appear to be useful in treating aseptic meningitis induced by
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6168.html" rel="external">
          "Acute treatment of migraine in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In many patients, headaches diminish after the first few infusions, although some individuals develop a recurrent pattern of symptoms occurring at seemingly reproducible intervals after each infusion. If headaches do not diminish, switching to more frequent, smaller doses of SCIG may also be helpful (if appropriate for the underlying disorder).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delayed headache
         </strong>
         – A small percentage of patients develop more serious headaches, particularly those with a history of migraine or those receiving high doses of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (eg, 1 to 2 g/kg) for autoimmune diseases, such as immune thrombocytopenia (ITP) [
         <a href="#rid15">
          15,34
         </a>
         ]. These more significant headaches may be delayed by as much as 48 to 72 hours following the infusion and may be accompanied by photophobia, nausea and vomiting, and/or other symptoms of migraine [
         <a href="#rid35">
          35
         </a>
         ]. As noted above, a two- to three-day course of a glucocorticoid may be needed in some cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The delay reported between the end of the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion and the onset of severe headache may suggest that these more severe headaches may be related to immunologic reactions that develop as the exogenous antibodies enter the central nervous system. Nuchal rigidity and/or other signs of meningismus may also be present as well as fever, suggesting that there is a continuum of symptoms, extending to include aseptic meningitis with pleocytosis. The evaluation for possible meningitis is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The mechanism of severe IVIG-associated headache is incompletely understood, and there may be many possible causes.
        </p>
        <p>
         In one study of patients receiving 2 g/kg of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         for neuromuscular diseases, 11 percent developed severe headache accompanied by other signs suggesting aseptic meningitis, a rate much higher than that in most studies [
         <a href="#rid15">
          15
         </a>
         ]. Five of these patients subsequently underwent lumbar puncture within 48 hours, which showed neutrophilic pleocytosis in four and increased cerebral spinal fluid (CSF) IgG concentrations in all five. Headaches were not prevented by changing the brand of IVIG, fractionating the dose, or administering glucocorticoids. This study suggests that some of the severe headaches may be due to meningeal irritation and/or inflammation caused by antibody-antigen reactions or by the IgG itself.
        </p>
        <p class="headingAnchor" id="H945815986">
         <span class="h2">
          Volume overload (TACO)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusion-associated circulatory overload (TACO) is a syndrome of pulmonary edema due to volume overload. This is more likely to occur in patients with preexisting cardiac or renal disease, particularly because of the high volume of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         used to treat autoimmune disorders (in the range of 1 to 2 grams/kg daily dose). Approximately 10 mL of fluid is administered per gram of IVIG.
        </p>
        <p>
         Signs and symptoms include dyspnea, orthopnea, headache, tachycardia, and/or hypertension. Evaluation and management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7919.html" rel="external">
          "Transfusion-associated circulatory overload (TACO)"
         </a>
         .)
        </p>
        <p>
         Risk for volume overload should be determined prior to each
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion, and diuretics can be used for patients with increased risk. For individuals who have experienced signs and symptoms of volume overload with IVIG, future infusions can be given more slowly with diuretics. Preparations that are more concentrated or have lower salt content may be used. SCIG is another option.
        </p>
        <p class="headingAnchor" id="H337962530">
         <span class="h2">
          TRALI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusion-related acute lung injury (TRALI) is a transfusion reaction that causes acute respiratory distress; it may initially be challenging to distinguish from TACO, although certain features such as fever or hypotension may be helpful in differentiating TRALI from TACO  (
         <a class="graphic graphic_table graphicRef86939" href="/z/d/graphic/86939.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
         Evaluation, management, and pathophysiology are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)"
         </a>
         .)
        </p>
        <p>
         TRALI is thought to be product-specific, and the manufacturer should be notified of the reaction and lot number. Subsequent infusions of other products or lot numbers are not expected to cause additional reactions.
        </p>
        <p class="headingAnchor" id="H659882">
         <span class="h1">
          DELAYED REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some adverse events can occur during the infusion or a few days afterwards; these represent approximately 40 percent of all adverse reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ]. These include thromboembolic events or complications affecting the kidney or blood cells  (
         <a class="graphic graphic_table graphicRef129468" href="/z/d/graphic/129468.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3606853">
         <span class="h2">
          Thromboembolic events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thromboembolic events may accompany or follow
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions, and prescribing information for all IVIG products includes a Boxed Warning about this risk [
         <a href="#rid36">
          36
         </a>
         ]. The frequency of these events is likely to depend on the dose and infusion rate of IVIG, the underlying indication, and patient-related factors such as immobility.
        </p>
        <p>
         Because of the association between
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and thromboembolic events, the placement of indwelling intravenous catheters solely for the purpose of administering IVIG is not recommended.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – The risk of thromboembolic events is of particular concern when high-dose therapy (≥1 g/kg) is used and administered rapidly. In a case-control study that compared 19 individuals who experienced a thromboembolic event with 38 age-matched controls (median age, 71 years), a trend towards increased thromboembolic risk that did not reach statistical significance was suggested if two or more cardiovascular risk factors (smoking, coronary artery disease, cerebrovascular disease, diabetes, hypertension, hyperlipidemia) were present (odds ratio [OR] 1.3, 95% CI 0.45-4.30); this increased risk became statistically significant when four or more of these risk factors were present (OR 10.5; 95% CI 1.91-57.58) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other data suggest that hereditary hypercoagulable states, hyperviscosity, malignancy, indwelling catheters, autoimmunity or connective tissue disease, older age, estrogen use, previous thrombotic events, and immobilization may also increase risk [
         <a href="#rid2">
          2
         </a>
         ]. Hyperviscosity may occur with dehydration, syndromes such as cryoglobulinemia or monoclonal gammopathies, or human immunodeficiency virus (HIV) infection; hyperviscosity may also be due to components of the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         product itself (sugars, osmotically active stabilizers, immunoglobulins) [
         <a href="#rid16">
          16,37-40
         </a>
         ]. In a series of 2724 first-time IVIG infusions in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma, the incidence of arterial embolic events was increased during the first day (from a baseline of 1.8 percent to 2.5 percent) [
         <a href="#rid17">
          17
         </a>
         ]. Patients with no identified risk factors may also develop thromboembolic complications [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The US Food and Drug Administration (FDA) worked with an
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         manufacturer to incorporate steps to reduce the levels of procoagulant factors, after clotting factors were suggested to be implicated in some thromboembolic events in the past [
         <a href="#rid14">
          14,42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sites
         </strong>
         – Sites of thrombosis may be arterial (in approximately 80 percent) or venous, and include acute coronary syndrome, myocardial infarction, transient cerebral ischemia attack, stroke, deep vein thrombosis, and pulmonary embolism [
         <a href="#rid41">
          41,43-49
         </a>
         ]. Local thrombosis at the site of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion can also occur, with extension from the extremity to larger veins [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing
         </strong>
         – Timing of thromboembolic events is variable. In one series from a neurology center in which 62 patients were treated with a total of 616 courses of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         over two years, thromboembolic events occurred in seven patients (11 percent) [
         <a href="#rid53">
          53
         </a>
         ]. In five patients, the event occurred within two weeks of treatment. This rate is somewhat higher than the overall background rate of approximately 0.8 events per 1000 kg of IVIG distributed, or 1 event per 10,000 courses of 100 grams [
         <a href="#rid54">
          54
         </a>
         ]. Other reports suggest arterial events are more likely to occur within hours to days of an infusion, whereas venous events are more likely to occur after days to weeks [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – The risk of thromboembolism can be minimized by ensuring adequate hydration and avoiding prolonged immobilization (eg, airplane travel) in the days following the infusion. Additional strategies in patients at high risk of thromboembolic complications include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid administration of large doses in a single day; doses can be divided such that no more than 500 mg/kg is administered per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administer
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         at relatively slow rates, such as below 3000 mg/hour or 50 mg/kg/hour and avoid "as-tolerated" dose escalations [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use products with a lower osmolarity for patients at risk of hyperviscosity  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assess blood viscosity in patients with hyperviscosity syndromes. Patients are most likely to become symptomatic at viscosities in excess of 5 to 8 centipoise. In patients with values higher than this, it may be prudent to consider plasmapheresis to lower the viscosity prior to administering
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . However, this approach has not been formally studied.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Complications affecting the kidney
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prescribing information for all
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products includes a Boxed Warning about the risks of acute kidney injury (AKI), osmotic nephrosis, and death from kidney dysfunction. Additional complications such as hyponatremia can also occur.
        </p>
        <p class="headingAnchor" id="H584484">
         <span class="h3">
          Acute kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         AKI (abrupt decline in glomerular filtration rate) is a rare complication of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         that is estimated to occur with less than 1 percent of infusions [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Risk factors for AKI from
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include [
         <a href="#rid56">
          56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age greater than 65 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preexisting chronic kidney disease (CKD; creatinine clearance &lt;60 mL/min)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes mellitus
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher doses of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypovolemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concomitant use of nephrotoxic agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Very high titers of rheumatoid factor
        </p>
        <p>
        </p>
        <p>
         Clinical manifestations vary from an asymptomatic rise in the plasma creatinine concentration to anuria. Spontaneous resolution typically occurs within 4 to 10 days after
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is discontinued [
         <a href="#rid56">
          56
         </a>
         ]. However, permanent kidney failure has been reported. AKI has mostly occurred with IVIG products containing sucrose and led to the discontinuation of these products, although other stabilizing agents have been implicated as well [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
         The pathogenesis is believed to involve an osmotic mechanism, similar to that of "sucrose nephropathy," in which sugar is taken up by tubular cells and the increased solute load causes the cells to become vacuolated, swell, and obstruct the tubules, creating a histopathologic lesion referred to as osmotic nephrosis [
         <a href="#rid59">
          59-62
         </a>
         ]. Additional mechanisms that may apply in some patients include renal heme pigment injury related to hemolysis, increased blood viscosity, and immune complex deposition [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Strategies to minimize the risk of AKI include ensuring adequate hydration prior to starting the infusion and avoiding administration of large doses in a single day; doses can be divided such that no more than 500 mg/kg is administered per day  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H584499">
         <span class="h3">
          Hyponatremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyponatremia is a rare complication of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         that can occur in individuals with underlying CKD or those who develop AKI from the IVIG therapy [
         <a href="#rid64">
          64
         </a>
         ]. The mechanism is dilutional and is thought to involve the inability of the kidney to handle the free water load in the setting of an underlying defect in free water excretion. Free water comes from the IVIG solution as well as from translocation of water from the intracellular to the extracellular compartment as a result of high concentrations of maltose in one IVIG solution [
         <a href="#rid65">
          65-67
         </a>
         ].
        </p>
        <p>
         It is important to distinguish true hyponatremia, which is associated with decreased serum osmolality, from pseudohyponatremia, which is a laboratory artifact (see
         <a class="local">
          'Laboratory abnormalities that do not require evaluation'
         </a>
         below), because patients with pseudohyponatremia should not have free water restriction, which in turn could increase the risk of other complications of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         A clue to pseudohyponatremia is a concomitant normal serum osmolality [
         <a href="#rid69">
          69
         </a>
         ]. Distinction between true hyponatremia and pseudohyponatremia using measurement of serum osmolality is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2354.html" rel="external">
          "Diagnostic evaluation of adults with hyponatremia"
         </a>
         .)
        </p>
        <p>
         Management of hyponatremia is also presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">
          "Overview of the treatment of hyponatremia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Hematologic complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematologic complications of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include hemolysis and neutropenia; these are usually transient.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically significant hemolytic anemia has been reported after
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusion [
         <a href="#rid1">
          1,63,70-77
         </a>
         ]. The mechanism involves passive transfer of antibodies present in the IVIG product, referred to as isoagglutinins, that react with red blood cell (RBC) antigens, predominantly of the ABO blood group system (anti-A and anti-B). In mild cases, an antibody may be demonstrated as a positive direct antiglobulin (Coombs) test (DAT), although this is not always seen because antibody-sensitized RBCs may be cleared rapidly.
        </p>
        <p>
         Confirmatory testing requires demonstration that the antibody is reactive with blood group A or B cells in the eluate. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Antibody screen'
         </a>
         .)
        </p>
        <p>
         Mild hemolysis with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions may result in transient anemia with reticulocytosis. Intravascular hemolysis may manifest with a decreased serum haptoglobin level and increased lactate dehydrogenase (LDH), and acute severe intravascular hemolysis can cause hemoglobinemia, hemoglobinuria, and kidney damage/dysfunction.
        </p>
        <p>
         Product-related risk factors for hemolysis include high-dose infusions (1 to 2 grams per kg per day), high
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         doses (eg, &gt;100 grams), female sex, and non-O blood group [
         <a href="#rid63">
          63,78-80
         </a>
         ]. This was illustrated in a series of 1000 patients receiving IVIG in which 16 cases of hemolysis were identified (1.6 percent) [
         <a href="#rid78">
          78
         </a>
         ]. Factors present in more than half the patients with hemolysis included a large dose of IVIG, non-O blood group, increased inflammatory markers such as increased erythrocyte sedimentation rate (ESR), and female sex. The onset of hemolysis ranged from 12 hours to 10 days, and the mean decrease in hemoglobin was 3.2 g/dL. Some primary immune deficiencies are associated with increased risk of autoimmune hemolytic anemia (AIHA). (See
         <a class="medical medical_review" href="/z/d/html/16362.html" rel="external">
          "Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency", section on 'Cytopenias'
         </a>
         .)
        </p>
        <p>
         We usually suggest testing for hemolysis five to seven days after the infusion. The hemolytic screen includes DAT, hemoglobin level, reticulocyte count, haptoglobin, and LDH  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 8
         </a>
         ) for patients receiving high-dose infusions and non-O blood group as well as individuals who have had a prior episode of hemolysis associated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or prior evidence of an anti-A and/or anti-B antibody. A positive antiglobulin test following the infusion is evaluated by testing for antibody specificity and hemolysis and addressed as appropriate (see
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Diagnostic approach'
         </a>
         ). If IVIG is being used to treat a condition responsible for hemolysis, then the infusion should proceed with caution.
        </p>
        <p>
         Some manufacturers have been developing additional steps in the manufacturing process such as immunoaffinity chromatography that decrease isoagglutinins [
         <a href="#rid81">
          81,82
         </a>
         ]. When applied to the Privigen product  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ), this resulted in an approximately 90 percent reduction in isoagglutinins, without apparent effect on product quality [
         <a href="#rid82">
          82,83
         </a>
         ]. Donor screening for anti-A and anti-B may also be used.
        </p>
        <p>
         For patients with clinically severe hemolysis and a positive anti-A and/or anti-B antibody due to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , we would avoid re-administering a product with the same lot number. Switching brands of IVIG may be helpful [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Compatibility testing (crossmatch)'
         </a>
         .)
        </p>
        <p>
         When appropriate, subcutaneous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (SCIG) may also be substituted as almost all cases of hemolysis are associated with the high doses given by the intravenous route of administration, with only rare reports of hemolysis associated with subcutaneous administration [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         If anemia resulting from hemolysis due to anti-A and/or anti-B is severe enough to require transfusion, it is recommended to transfuse group O RBCs, to avoid the possibility of further hemolysis [
         <a href="#rid84">
          84
         </a>
         ]. Discussion with the transfusion medicine service or blood bank is advised. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Washed red cells'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Neutropenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neutropenia is a rare complication of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and we do not routinely evaluate for neutropenia following IVIG infusion. However, we do obtain a complete blood count (CBC) as part of monitoring for hemolysis. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Monitoring'
         </a>
         .)
        </p>
        <p>
         Neutropenia may be appreciated in patients being evaluated for transfusion-related acute lung injury (TRALI) or a possible infection [
         <a href="#rid85">
          85-87
         </a>
         ]. If a patient develops neutropenia in the setting of TRALI, the specific product would not be given again to that recipient, and the product would be reported to the blood bank or to adverse event reporting through the manufacturer. (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)"
         </a>
         .)
        </p>
        <p>
         Neutropenia associated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         may be due to neutrophil margination to the vascular wall upon activation by complement or immune globulins in the IVIG product. Another mechanism involves immune clearance induced by antineutrophil antibodies or antibodies to "sialic acid-binding Ig-like lectin 9" (Siglec-9) in IVIG [
         <a href="#rid88">
          88,89
         </a>
         ]. In some cases, neutropenia may be a feature of an underlying immunodeficiency rather than a complication of the IVIG. In most instances, neutropenia is transient, and intervention is not required [
         <a href="#rid87">
          87,90,91
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H660184">
         <span class="h1">
          LATE REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse events that may occur weeks to months after receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include dermatologic reactions, impaired vaccination response, and the theoretical (but highly unlikely) risk of an infectious agent transmitted from the IVIG product.
        </p>
        <p>
         Other reactions possibly related to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include case reports of necrotizing enterocolitis in premature infants, ileitis in adults, uveitis, hypothermia, non-infectious hepatitis, and serum sickness with arthritis [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6924704">
         <span class="h2">
          Dermatologic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eczematous dermatitis associated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         therapy has been described in 64 cases, mostly in patients receiving high doses for neurologic diseases [
         <a href="#rid92">
          92
         </a>
         ]. This often occurs in patients with preexisting dermatologic disease. A vesicular eruption of the palms or soles (dyshidrotic eczema), appearing within eight days of administration, was a characteristic presentation. Most patients were successfully treated with topical corticosteroids, with resolution within three weeks. However, reactions tended to recur with subsequent IVIG treatments, requiring ongoing therapy. A few cases of alopecia, erythema multiforme, and baboon syndrome have been reported [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">
          "Acute palmoplantar eczema (dyshidrotic eczema)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3523128">
         <span class="h2">
          Effects on vaccine efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         can impair a patient's response to live virus vaccines, which must replicate in the host to deliver an immunogenic antigen load. Thus, the timing of some vaccinations, particularly against measles, mumps, and rubella, may need to be changed to achieve optimal immunization.
        </p>
        <p>
         An annual
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         is recommended for most patients; this should not interfere with or interrupt
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         administration.
        </p>
        <p>
         Patients who require vaccination with certain live-virus vaccines (eg, measles vaccine) should follow appropriate recommendations regarding the timing of administration relative to the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (
         <a class="graphic graphic_table graphicRef72640" href="/z/d/graphic/72640.html" rel="external">
          table 9
         </a>
         ). This is because antibodies present in the IVIG may interfere with the normal immune response to the vaccine and hence reduce vaccine efficacy. (See
         <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">
          "Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Recent receipt of immune globulin or blood'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101273.html" rel="external">
          "Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Recent receipt of blood or immune globulin'
         </a>
         .)
        </p>
        <p>
         If supplies of a critical vaccine are limited and the vaccine is available, it can be administered without delay. If there is less urgency, it may be prudent to give a vaccine two weeks before or after the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , primarily to allow distinction between adverse reactions to the vaccine versus the IVIG. This recommendation is consistent with guidance from the Australasian Society of Clinical Immunology and Allergy related to coronavirus disease 2019 (COVID-19) vaccination [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Infectious risks
         </span>
         <span class="headingEndMark">
          —
         </span>
         The manufacturing process of available
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products reduces the risk of transmission of viruses and prions. No product produced with current safety measures has ever been reported to have transmitted a bloodborne disease, and no transmission of Creutzfeldt-Jakob disease or other human prion-mediated disorder has been reported in any patient receiving IVIG. No cases of HIV infection have been reported. One cannot be certain that available measures will remove or inactivate all potential (and as yet undescribed) clinically significant pathogens.
        </p>
        <p>
         Parvovirus B19 is not destroyed by solvent detergent or heat treatment; however, it is thought that antibodies to parvovirus present in the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         preparations are sufficient to prevent clinical infection [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Despite the safety of available
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products, historical cases of infectious transmission have been reported. As an example, during a six-month period in 1994, 112 cases of hepatitis C virus (HCV) infection associated with the use of IVIG were reported to the United States Centers for Disease Control [
         <a href="#rid94">
          94
         </a>
         ]. Additional cases were reported in Europe [
         <a href="#rid95">
          95
         </a>
         ]. Steps were subsequently added to the plasma procurement and IVIG processing procedures to reduce risks of transmission of bloodborne pathogens.
        </p>
        <p>
         Further measures taken by the manufacturer include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All plasma is derived from United States donors (for products used in the United States).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma donors must complete a detailed questionnaire about risk factors and possible exposures. (See
         <a class="medical medical_review" href="/z/d/html/7949.html" rel="external">
          "Blood donor screening: Overview of recipient and donor protections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Each unit of donated plasma is tested for known viruses by antigen and nucleic acid testing (NAT; eg, polymerase chain reaction); and for elevations of hepatic transaminases, which may alert the laboratory of a viral infection not detected by available assays. (See
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Donated units of plasma that pass these tests are then subject to quarantine until a subsequent donation from the same donor has been obtained, tested, and found to be free of pathogens. Only then can the previous donation be pooled. NAT is then repeated as the units of plasma are pooled.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Each manufacturer must employ multiple complementary purification and virus inactivation/removal steps in the production process. These include ethanol or polyethylene glycol (PEG) precipitation, caprylate and/or other fatty acid treatment, depth filtration, and chromatography steps, which result in multiple log fold reductions of test viruses  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ). These are combined with additional steps specifically intended to inactivate viruses, such as solvent/detergent treatment or pasteurization (prolonged treatment at 60°C), which destroy the envelopes of viruses such as HCV, HIV, and West Nile virus [
         <a href="#rid96">
          96,97
         </a>
         ]. Nanofiltration, also termed "virus filtration," is performed with several products to remove nonenveloped viruses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional quality control is performed by testing the recovery of animal pathogens that are introduced into test lots of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products (which are used only for testing and are not administered to patients) [
         <a href="#rid97">
          97-99
         </a>
         ]. These procedures have been shown to inactivate or remove the following animal pathogens:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bovine diarrhea virus, an enveloped RNA virus that serves as a model for HCV.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pseudorabies, a large, enveloped DNA virus that serves as a model for human herpes-family viruses.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reovirus, a nonenveloped RNA virus.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A porcine parvovirus that serves as a model for human parvovirus B19.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rodent-adapted hamster scrapie, a model for prion diseases.
        </p>
        <p>
        </p>
        <p>
         In addition, recommendations for improved record keeping and monitoring of patients have been developed [
         <a href="#rid100">
          100
         </a>
         ]. The dose, brand, lot number, expiration date, and manufacturer of any
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         product infused into any patient should be recorded in the medical record, as done for blood products. Furthermore, patients should be encouraged to keep their own logs of this information. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H584914">
         <span class="h1">
          LABORATORY ABNORMALITIES THAT DO NOT REQUIRE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         has a variety of transient effects on laboratory tests that are generally considered not to be clinically important and should not be investigated in the absence of concerning symptoms. However, it may be helpful to be aware of these changes to avoid an extensive evaluation and/or interventions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viscosity/ESR
         </strong>
         –
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         increases serum viscosity and may alter the erythrocyte sedimentation rate (ESR) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sodium
         </strong>
         – Pseudohyponatremia can also be seen due to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         administration [
         <a href="#rid68">
          68,101,102
         </a>
         ]. This phenomenon is due to the protein load, which increases the nonaqueous phase of plasma. Because the concentration of sodium is physiologically regulated in the aqueous phase, but the laboratory sodium determination uses the total plasma volume of the sample, an artifactual dilution of sodium results. (See
         <a class="medical medical_review" href="/z/d/html/2374.html" rel="external">
          "Causes of hypotonic hyponatremia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with underlying kidney disease may develop true hyponatremia, as discussed above. (See
         <a class="local">
          'Hyponatremia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osmolality
         </strong>
         – Maltose accumulation can also lead to an osmolal gap, as the measured plasma osmolality is greater than that estimated from the contributions of sodium, potassium, glucose, and urea. Affected patients are not at risk for symptoms of hyponatremia, since the plasma osmolality is modestly increased, not reduced. Maltose may also give false readings with glucose meters that use test strips containing glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ) or glucose-dye-oxidoreductase (GDO) [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serologies
         </strong>
         – Serologic tests for various antibodies (especially antiviral titers, but possibly also antinuclear antibodies [ANA], antineutrophil cytoplasmic antibodies [ANCA], rheumatoid factor) may become falsely positive due to the passively transmitted antibodies in
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . These serologic tests are unreliable following an infusion since it is difficult (unless the patient has agammaglobulinemia) to determine if the patient or the donor pool is the source of the antibodies. Since the half-life of IgG is 21 to 28 days, this effect should not persist beyond 60 days, and it should not affect assays for IgM or IgA antibodies. Polymerase chain reaction testing for specific viruses can be helpful in distinguishing passively transferred antibodies from prior infection in some settings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coombs
         </strong>
         – A positive direct antiglobulin (Coombs) test (DAT) without clinically apparent hemolysis may be seen transiently in as many as 30 percent of patients receiving high-dose
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . Evaluation of a newly positive DAT is discussed above (see
         <a class="local">
          'Hemolysis'
         </a>
         above). However, a known positive DAT, especially if associated with the patient's underlying condition, does not require further intervention if there is no evidence of hemolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta-D-glucan
         </strong>
         – Some
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products may cause false-positive results on the beta-D-glucan assay, a test for the detection of systemic aspergillus. (See
         <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">
          "Diagnosis of invasive aspergillosis", section on 'Beta-D-glucan assay'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Adverse reactions occur with up to 5 to 15 percent of all intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) infusions and affect 20 to 50 percent of individuals receiving IVIG. Risk factors include those related to the product (higher doses, faster infusion rates) and the patient's underlying condition (hyperviscosity states, organ dysfunction, and/or prothrombotic stimuli). Anaphylactic reactions due to anti-IgA in individuals with IgA deficiency are extremely rare. Reactions are most likely to occur during the first infusion or after changing brands. (See
         <a class="local">
          'Incidence and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SCIG versus IVIG
         </strong>
         – Systemic reactions to subcutaneous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (SCIG) are much lower than to IVIG, with the exception of local reactions such as pain, swelling, and redness at the infusion sites, which are more common with SCIG. (See
         <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">
          "Subcutaneous and intramuscular immune globulin therapy", section on 'Comparison of SCIG with IVIG'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General strategies
         </strong>
         – General strategies for minimizing the risk of adverse reactions to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include ensuring adequate hydration, treating infections before initiating therapy, starting with a slow infusion rate, and avoiding substitution of another brand once a well-tolerated preparation has been identified  (
         <a class="graphic graphic_table graphicRef129468" href="/z/d/graphic/129468.html" rel="external">
          table 1
         </a>
         ). Some clinicians give the first dose in the hospital, especially for individuals with known risk factors. (See
         <a class="local">
          'Strategies for reducing adverse events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premedications
         </strong>
         – Individuals who have not had a prior reaction are likely to tolerate subsequent infusions, and we generally omit premedications  (
         <a class="graphic graphic_algorithm graphicRef130102" href="/z/d/graphic/130102.html" rel="external">
          algorithm 2
         </a>
         ). For individuals who have had a prior reaction to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , we suggest premedication to reduce recurrence of the reaction (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The premedications and doses are individualized. (See
         <a class="local">
          'Premedications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anaphylaxis
         </strong>
         – Anaphylaxis to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is extremely rare but may be life-threatening. Many clinicians administer the initial dose in a monitored setting. The diagnosis is made clinically; laboratory testing (levels of anti-IgA, serum tryptase) can be obtained for later review. The cause is often an IgA-deficient individual with anti-IgA antibodies (predominantly IgE) that can react with IgA in the infused product. However, most IgA-deficient individuals tolerate IVIG without difficulty, and low levels of IgA (as opposed to undetectable levels) are not considered a risk factor for anaphylaxis. (See
         <a class="local">
          'Anaphylaxis and anaphylaxis-like reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment of anaphylaxis is outlined in tables for children  (
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ) and adults  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 4
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals with true anaphylaxis due to anti-IgA, avoidance of future
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is ideal, but if not possible, switching to SCIG or using a product with the lowest amount of IgA  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ) are reasonable alternatives. Pretreatment with antihistamines and/or glucocorticoids and giving the initial infusion at a very slow rate are also useful. (See
         <a class="local">
          'Preparation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic reactions
         </strong>
         – For those with allergic symptoms that in retrospect are determined not to be true anaphylaxis, subsequent infusions are generally tolerated with diminution of symptoms. Use of premedications is individualized based on the severity of the reaction and clinician and patient preferences. (See
         <a class="local">
          'Patients who do not have true anaphylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TRALI
         </strong>
         – Transfusion-related acute lung injury (TRALI) does not tend to recur if the implicated product is avoided. (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammatory reactions
         </strong>
         – Inflammatory (phlogistic) reactions including pain, systemic symptoms, and headache are managed symptomatically  (
         <a class="graphic graphic_table graphicRef129468" href="/z/d/graphic/129468.html" rel="external">
          table 1
         </a>
         ). Bacterial infections should be identified, and treatment initiated, before the first dose of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . Individuals with a history of headache with IVIG can receive premedication with antihistamines or anti-migraine therapies if there is a history of migraines. (See
         <a class="local">
          'Pain or systemic (influenza-like) symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Volume overload (TACO)
         </strong>
         – Volume overload is managed using slower infusions, products with lower salt concentrations, and diuretics. (See
         <a class="local">
          'Other immediate reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombosis
         </strong>
         – Thromboembolic events (myocardial infarction, stroke, venous thromboembolism) may accompany or follow
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions, and prescribing information for all IVIG products includes a Boxed Warning about this risk. We avoid placing indwelling intravenous catheters solely for the purpose of administering IVIG. Other strategies to minimize these events include ensuring adequate hydration, avoiding prolonged immobilization, spacing large doses over several days, and slowing infusions. For individuals with a history of thromboembolic events related to IVIG, low osmolarity products may be used. (See
         <a class="local">
          'Thromboembolic events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute kidney injury (AKI) and hyponatremia
         </strong>
         – Complications affecting the kidney may accompany or follow
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         infusions, and prescribing information for all IVIG products includes a Boxed Warning about these risks. Strategies to minimize AKI include ensuring adequate hydration and avoiding more concentrated products in those with underlying kidney disease  (
         <a class="graphic graphic_table graphicRef116460" href="/z/d/graphic/116460.html" rel="external">
          table 2
         </a>
         ). Hyponatremia can also occur and must be distinguished from pseudohyponatremia. (See
         <a class="local">
          'Complications affecting the kidney'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolysis and neutropenia
         </strong>
         – Hemolytic anemia can occur when antibodies in the
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         product react with red blood cell (RBC) antigens (A and/or B; infrequently RhD). Reactions can range from direct antiglobulin (Coombs) test-positivity, mild extravascular hemolysis, and rarely, intravascular hemolysis. Risk factors include high dose, female sex, and non-O blood group. Neutropenia can occur but is generally mild and transient. (See
         <a class="local">
          'Hematologic complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other reactions
         </strong>
         – Eczematous dermatitis or reduced efficacy of vaccinations may occur days to weeks following the infusion.
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products are extremely unlikely to transmit viruses or prions; however, a theoretical risk exists and information about brand, lot number, expiration date, and manufacturer should be retained for each dose. IVIG can also cause laboratory abnormalities that are generally not considered clinically important. (See
         <a class="local">
          'Late reactions'
         </a>
         above and
         <a class="local">
          'Laboratory abnormalities that do not require evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4132728717">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
        </p>
        <p>
         The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor, to earlier versions of this topic review.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges extensive contributions of Arthur J Silvergleid, MD, who contributed as an author, to earlier versions of this and many other topic reviews.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lozeron P, Not A, Theaudin M, et al. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease. Muscle Nerve 2016; 53:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waheed W, Ayer GA, Jadoo CL, et al. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease. Muscle Nerve 2019; 60:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Tian X, Wang X, Xiao Z. Adverse Effects of Immunoglobulin Therapy. Front Immunol 2018; 9:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 2004; 136:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006; 91:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elmarsafy A, Galal NM, Abdallah SM, et al. Detection of Complications Following Intravenous Immunoglobulins Infusion in A Cohort of Egyptian Children. J Clin Cell Immunol 2015; 6:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy 2013; 3:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Struff WG, Klasser M, Eckert V, Dietrich RL. Safety monitoring of a polyvalent immunoglobulin preparation: documentation of 15,548 administrations. Int J Clin Pharmacol Ther 2005; 43:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan VM, Salomé-Bentley NJ, Chapel HM, Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caress JB, Hobson-Webb L, Passmore LV, et al. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009; 256:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammann EM, Jones MP, Link BK, et al. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 2016; 127:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm 2019; 6:e590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbas A, Rajabally YA. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. Curr Drug Saf 2019; 14:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams SJ, Gupta S. Anaphylaxis to IVIG. Arch Immunol Ther Exp (Warsz) 2017; 65:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björkander J, Hammarström L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987; 7:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baudel JL, Vigneron C, Pras-Landre V, et al. Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. Clin Rheumatol 2020; 39:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oltean S, Epure A, Lindström K, Pardi C. Detection of anti-IgA antibodies using the particle gel immunoassay: a rapid test for increased patient safety. Blood Transfus 2014; 12:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundin U, Nava S, Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000; 20:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007; 122:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira A, Garcia Rodriguez MC, Lopez-Trascasa M, et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol 1988; 47:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torabi Sagvand B, Mirminachi B, Abolhassani H, et al. IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin. Allergol Immunopathol (Madr) 2015; 43:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaba S, Keskindemirci G, Aydogmus C, et al. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience. Eur Ann Allergy Clin Immunol 2017; 49:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finkel AG, Howard JF Jr, Mann JD. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications. Headache 1998; 38:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 2000; 22:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathy I, Gille M, Van Raemdonck F, et al. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 1998; 98:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ovanesov MV, Menis MD, Scott DE, et al. Association of immune globulin intravenous and thromboembolic adverse events. Am J Hematol 2017; 92:E44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 2003; 24 Suppl 4:S222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidar M, Masarwa S, Rotman P, et al. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature. Immunol Res 2018; 66:668.
          </a>
         </li>
         <li class="breakAll">
          FDA approves US market return for octagam following Octapharma's implementation of enhanced safety measures. PR Newswire. Available at: https://www.prnewswire.com/news-releases/fda-approves-us-market-return-for-octagam-following-octapharmas-implementation-of-enhanced-safety-measures-133246738.html (Accessed on July 07, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaidan R, Al Moallem M, Wani BA, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003; 10:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000; 59:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001; 57:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizrahi M, Adar T, Orenbuch-Harroch E, Elitzur Y. Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion. Case Rep Med 2009; 2009:861370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benadiba J, Robitaille N, Lambert G, et al. Intravenous immunoglobulin-associated thrombosis: is it such a rare event? Report of a pediatric case and of the Quebec Hemovigilance System. Transfusion 2015; 55:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinod KV, Kumar M, Nisar KK. High dose intravenous immunoglobulin may be complicated by myocardial infarction. Indian J Crit Care Med 2014; 18:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000; 75:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz KA, Hivnor CM, Geist DE, et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003; 139:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 2011; 308:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013; 105:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fakhouri F. [Intravenous immunoglobulins and acute renal failure: mechanism and prevention]. Rev Med Interne 2007; 28 Spec No. 1:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48:518.
          </a>
         </li>
         <li class="breakAll">
          FDA drug warning 1998.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang R, Szerlip HM. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South Med J 2000; 93:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantú TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahsan N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994; 154:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. Clin Exp Nephrol 2006; 10:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palevsky PM, Rendulic D, Diven WF. Maltose-induced hyponatremia. Ann Intern Med 1993; 118:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollander RC. Recognizing maltose-induced hyponatremia. Ann Intern Med 1994; 120:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106:c143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn N, Wijdicks EF, Burritt MF. Intravenous immune globulin and pseudohyponatremia. N Engl J Med 1998; 339:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liamis G, Liberopoulos E, Barkas F, Elisaf M. Spurious electrolyte disorders: a diagnostic challenge for clinicians. Am J Nephrol 2013; 38:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura S, Yoshida T, Ohtake S, Matsuda T. Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol 1986; 76:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987; 82:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comenzo RL, Malachowski ME, Meissner HC, et al. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed M, Bates G, Eastley B. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy. Br J Haematol 2013; 160:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinti I, Pulvirenti F, Milito C, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion 2015; 55:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pendergrast J, Armali C, Callum J, et al. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Transfusion 2021; 61:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: A case series analysis. Transfusion 2008; 48:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4:1993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branch DR, Hellberg Å, Bruggeman CW, et al. ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis. Blood 2018; 131:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siani B, Willimann K, Wymann S, et al. Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening. Biol Ther 2014; 4:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoefferer L, Glauser I, Gaida A, et al. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion 2015; 55 Suppl 2:S117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerber S, Gaida A, Spiegl N, et al. Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: Industry-scale assessment. BioDrugs 2016; 30:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pintova S, Bhardwaj AS, Aledort LM. IVIG--a hemolytic culprit. N Engl J Med 2012; 367:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh A, Arif F, Smith SD. Intravenous immunoglobulin-induced reversible neutropenia in a renal transplant patient. Clin Nephrol 2005; 64:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992; 326:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol 2005; 27:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lassiter HA, Bibb KW, Bertolone SJ, et al. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol 1993; 15:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Gunten S, Schaub A, Vogel M, et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108:4255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SB, Shin HJ. Neutropenia following intravenous immunoglobulin therapy in adult patients with immune thrombocytopenic purpura: A single center experience and literature review. Medicine (Baltimore) 2020; 99:e18624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkovitch M, Dolinski G, Tauber T, et al. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol 1999; 21:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2012; 66:312.
          </a>
         </li>
         <li class="breakAll">
          Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination. Australian Society of Clinical Immunology and Allergy. Available at: https://www.allergy.org.au/hp/papers/guide-immunodeficiency-autoimmunity-and-covid-19-vaccination (Accessed on July 07, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994; 43:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjøro K, Frøland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985; 25:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol 1996; 14 Suppl 15:S47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee DC, Stenland CJ, Hartwell RC, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994; 331:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bern M. Clinically significant pseudohyponatremia. Am J Hematol 2006; 81:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003; 73:97.
          </a>
         </li>
         <li class="breakAll">
          Maltose facts. Octapharma. Available at: www.octagamusa.com/octagam5/wp-content/uploads/sites/2/2019/12/Maltose_Fact_Sheet.pdf (Accessed on June 27, 2022).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3944 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14571392" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Risks associated with the use of intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23835249" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Adverse effects of human immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17917017" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Safety of IGIV therapy and infusion-related adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26467654" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31443119" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29951056" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Adverse Effects of Immunoglobulin Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530624" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Therapy with intravenous immunoglobulins: complications and side-effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15030521" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Increased risk of adverse events when changing intravenous immunoglobulin preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16638785" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Detection of Complications Following Intravenous Immunoglobulins Infusion in A Cohort of Egyptian Children
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24260730" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16163894" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Safety monitoring of a polyvalent immunoglobulin preparation: documentation of 15,548 administrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12869031" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28041678" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Update on the use of immunoglobulin in human disease: A review of evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037406" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19253011" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Case-control study of thromboembolic events associated with IV immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26443622" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31355323" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30332974" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27412077" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Anaphylaxis to IVIG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21835445" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3945295" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3494039" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31760541" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24887222" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Detection of anti-IgA antibodies using the particle gel immunoassay: a rapid test for increased patient safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9649200" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10798611" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17137841" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2450712" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25201762" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28120600" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9595875" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738845" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Drug-induced aseptic meningitis: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037414" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Aseptic meningitis and intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9922823" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28066925" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Association of immune globulin intravenous and thromboembolic adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347348" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of high-dose intravenous immunoglobulin therapy on blood rheology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8309562" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12796522" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14598047" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intravenous immunoglobulins in neurological disorders: safety issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30565202" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30565202" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12796539" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The clinical features of 16 cases of stroke associated with administration of IVIg.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12823487" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10627434" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11706114" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20182639" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25355613" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intravenous immunoglobulin-associated thrombosis: is it such a rare event? Report of a pediatric case and of the Quebec Hemovigilance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24872657" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : High dose intravenous immunoglobulin may be complicated by myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10630762" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12925384" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317619" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Safety of intravenous immunoglobulin (IVIG) therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21679973" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23398249" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Thromboembolic events associated with immunoglobulin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16391392" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Intravenous immunoglobulin: adverse effects and safe administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17768831" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : [Intravenous immunoglobulins and acute renal failure: mechanism and prevention].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10401909" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10401909" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11005352" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7847349" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Acute renal failure associated with immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8074604" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Intravenous immunoglobulin-induced osmotic nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18295066" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19628320" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16791398" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : True hyponatremia secondary to intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8442623" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Maltose-induced hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8110291" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Recognizing maltose-induced hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17596722" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9722438" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Intravenous immune globulin and pseudohyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23817179" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Spurious electrolyte disorders: a diagnostic challenge for clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6135031" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effect of intravenous immunoglobulin in immune thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2433882" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3765031" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hemolysis following intravenous immune globulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3826125" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hemolytic anemia following intravenous gamma globulin administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1593353" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23294261" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25532440" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33433931" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18466176" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: A case series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19833910" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305554" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24841428" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26174889" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27646589" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: Industry-scale assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22931280" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : IVIG--a hemolytic culprit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175954" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Intravenous immunoglobulin-induced reversible neutropenia in a renal transplant patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1727981" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Transient neutropenia induced by intravenous immune globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15750446" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8447553" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Neonatal immune neutropenia following the administration of intravenous immune globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16902148" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31895820" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Neutropenia following intravenous immunoglobulin therapy in adult patients with immune thrombocytopenic purpura: A single center experience and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10405875" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21601310" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21601310" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8022396" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7526215" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3934801" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12869106" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8828948" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Virus validation studies of immunoglobulin preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10644089" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969346" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Transmission of viral infections through intravenous immune globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16755556" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Clinically significant pseudohyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12749010" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
